In an asymptomatic patient with microscopic hematuria detected on a routine urinalysis, what evaluation is recommended and should the urinalysis be repeated?

Evaluation of Asymptomatic Microscopic Hematuria

First, confirm true microscopic hematuria by repeating the urinalysis with microscopy—a positive dipstick alone should never trigger a full workup. 1

Initial Confirmation Step

• Microscopic hematuria must be confirmed by microscopy showing ≥3 RBCs per high-power field (HPF) on a properly collected, uncontaminated specimen without evidence of infection. 1
• A dipstick reading alone is insufficient and leads to unnecessary evaluations and costs—up to 75% of dipstick-positive patients may not have true microscopic hematuria on microscopy. 2
• If the initial UA shows microscopic hematuria, repeat the UA with microscopy. 1

Exclude Benign Transient Causes Before Full Workup

Before proceeding with imaging and cystoscopy, assess for and exclude:

• Urinary tract infection: Obtain urine culture (preferably before antibiotics) and repeat UA after treatment—hematuria should resolve if infection was the cause. 1
• Recent vigorous exercise, menstruation, trauma, or recent urologic procedures: These patients are unlikely to benefit from complete imaging workup. 1
• Anticoagulation therapy does NOT alter the need for evaluation—proceed with standard workup. 1

If a benign transient cause is identified and treated, repeat the UA after resolution of that cause. 1 If hematuria persists on repeat testing (≥3 RBCs/HPF), proceed with full evaluation.

Risk Stratification and Evaluation Algorithm

Once true persistent microscopic hematuria is confirmed (≥3 RBCs/HPF on repeat UA without benign cause), the evaluation intensity depends on risk factors:

High-Risk Features (Require Full Evaluation):

• Age ≥35 years 1
• Male gender 1
• Smoking history (current or past) 1
• Occupational exposure to chemicals/dyes (benzenes, aromatic amines) 1
• History of gross hematuria 1
• History of pelvic irradiation 1
• Chronic UTI or irritative voiding symptoms 1
• Analgesic abuse 1

Full Urologic Evaluation Components:

For patients ≥35 years old OR those <35 years with risk factors, perform:

1. Upper tract imaging with CT urography (CTU) as the preferred modality—this includes unenhanced images followed by IV contrast with nephrographic and excretory phases. 1

   • Alternative if CTU unavailable: MR urography, retrograde pyelograms with non-contrast CT, or ultrasound (though these are less optimal). 1

2. Cystoscopy (flexible or rigid) to visualize the bladder mucosa, urethra, and ureteral orifices—this is essential to exclude bladder cancer. 1

   • All patients ≥35 years should undergo cystoscopy. 1
   • Patients <35 years without risk factors may defer initial cystoscopy, but this is a lower-yield population. 1

3. Renal function testing should be performed. 1

4. Voided urine cytology is NOT recommended as part of routine initial evaluation—it lacks sensitivity for low-grade tumors and does not obviate further workup if negative. 1, 3, 4

Patients <35 Years Without Risk Factors:

• Initial cystoscopy may be deferred in young patients without risk factors, as the yield is very low. 1
• However, upper tract imaging should still be considered if hematuria persists. 1

Special Considerations for Glomerular Disease

If the patient has dysmorphic RBCs, red cell casts, proteinuria, elevated creatinine, or hypertension:

• Concurrent nephrology referral is indicated for evaluation of renal parenchymal disease (glomerulonephritis). 1
• This does NOT preclude urologic evaluation—both evaluations should proceed in parallel. 1

Follow-Up After Negative Initial Evaluation

If the complete evaluation is negative:

• Engage in shared decision-making regarding repeat UA monitoring, particularly for high-risk patients (age >40, smokers, occupational exposures). 1
• Consider repeating UA at 6,12,24, and 36 months for persistent hematuria. 1
• Repeat anatomic evaluation (imaging and/or cystoscopy) within 3-5 years or sooner if clinically indicated for persistent microscopic hematuria. 1
• Immediate re-evaluation is warranted if: gross hematuria develops, abnormal cytology appears, or new irritative voiding symptoms occur without infection. 1

The diagnostic yield of repeat evaluation is low—in one study, only 1.2% of patients with persistent hematuria after negative workup developed bladder cancer on repeat cystoscopy, and 1.3% developed suspicious renal masses on repeat imaging, typically detected >36 months after initial evaluation. 5

Common Pitfalls to Avoid

• Never proceed with full urologic workup based on dipstick alone—always confirm with microscopy. 1, 2
• Do not skip evaluation in patients on anticoagulation—the presence of anticoagulation does not explain hematuria and should not alter the workup. 1
• Do not rely on urine cytology to rule out malignancy—negative cytology does not eliminate the need for cystoscopy and imaging. 1, 3, 4
• Ensure infection is truly treated and resolved before attributing hematuria solely to UTI—repeat UA after antibiotic course. 1